Topical medium-length PDRN enhances dermal extracellular matrix repair in photodamaged skin via PI3K-Akt/TGF-β-regulated pathways.

Summary

Mechanistic, delivery, and clinical data collectively show topical PDRN-850K activates PI3K-Akt/TGF-β/Smad signaling, penetrates viable epidermis, and enhances ECM repair in UV-damaged skin. In a randomized, double-blind split-face trial, 0.1% PDRN-850K eye cream produced roughly two-fold greater improvements in periocular wrinkles and dermal parameters than 0.1% retinol over 28 days with good tolerability.

Key Findings

• PDRN-850K activated PI3K-Akt, TGF-β/Smad, and autophagy-related signaling in basal human dermal fibroblasts; pathway inhibition attenuated ECM gene induction.
• Confocal Raman spectroscopy and auxiliary models showed time-dependent penetration of PDRN signal into viable epidermis.
• In UV-irradiated ex vivo human skin, PDRN-850K increased viable epidermal thickness and upregulated collagens, elastic fiber proteins, and YAP.
• In a randomized, double-blind split-face clinical study, 0.1% PDRN-850K achieved ~2-fold greater improvements in periocular wrinkles and dermal metrics versus 0.1% retinol over 28 days, with good tolerability.

Clinical Implications

Topical PDRN-850K may serve as a pro-repair alternative or adjunct to retinoids for periocular photoaging, offering improved tolerability and ECM remodeling with short-term efficacy.

Limitations

• Short clinical duration (28 days) and sample size not specified in the abstract.
• Outcomes focused on periocular area; generalizability to other facial regions and longer-term remodeling remains to be established.

Future Directions

Larger, longer RCTs across facial regions with biomarker-guided response, head-to-heads versus retinoids/peptides/growth factors, and open data/code for mechanistic reproducibility.